Magnesium Glycinate and GLP-1
Why 48% Mg deficiency + GLP-1 side effects create a formulation gap — and how to source bisglycinate with the right COA, grade specs, and supply chain reliability.
OFAME GROUP / B2B INTELLIGENCE SERIES
Ingredient Intelligence
Cutting through marketing noise to deliver verified science and regulatory clarity on functional ingredients.
Clinical dataSupply architectureCompliance guardrails
What We Deliver
Four Pillars of Intelligence
The series addresses the evidence, regulatory, procurement and disclosure questions behind functional ingredient decisions.
01 / EVIDENCE
Verified Science
Published analysis is structured around peer-reviewed literature, PMIDs and traceable market data where those references are available.
02 / BOUNDARIES
Regulatory Clarity
FDA, EFSA and TGA boundaries are considered alongside the distinction between structure/function language and disease claims.
03 / SOURCING
Procurement Intelligence
COA requirements, supplier qualification, grade specifications and supply-chain questions are treated as part of the ingredient brief.
04 / DISCLOSURE
Honest Disclosure
Counter-evidence, evidence gaps and commercial positions are identified transparently within the scope of each analysis.
Published Intelligence
Latest from the Series
Nine current briefing notes across mineral sourcing, women’s health, sleep, pet nutrition, sports nutrition and supply-chain intelligence.
GLP-1 · SOURCING01
WOMEN'S HEALTH · PCOS02
Magnesium Bisglycinate: Cornerstone Mineral for Women's Health
PCOS insulin resistance (SMD -0.75), leg cramp relief, and prenatal formulation stack — backed by clinical trial data and procurement-grade sourcing guidance.
PREMIUM SUPPLEMENTS03
Magnesium Bisglycinate: What the Premium Supplement Market Is Actually Optimizing For
Why premium brands are shifting from oxide to bisglycinate — bioavailability data, consumer willingness-to-pay, and the supply chain implications of grade differentiation.
SLEEP · RETAIL STRATEGY04
Glycine vs. Melatonin: Why Retail Access Is Reshaping Sleep Supplement Strategy
CVS 18+ restrictions, state-level legislation, and international regulatory divergence — what procurement teams should know before their next production run.
SLEEP · B2B POSITIONING05
Glycine vs. Melatonin: B2B Positioning for Sleep Supplement Strategy
A 5-dimension procurement framework comparing regulatory trajectory, evidence depth, cost structure, and portfolio versatility — with honest disclosure of glycine's limitations.
PET NUTRITION06
Glycine in Pet Nutrition: An Ingredient Intelligence Review
Why glycine remains underutilized in pet formulations despite strong biochemical rationale — and what brands need to know about species-specific evidence gaps and regulatory pathways.
SPORTS NUTRITION07
Why Smart Sports Nutrition Brands Are Repositioning Glycine
Beyond sleep: glycine's role in glutathione synthesis, collagen synergy, and recovery infrastructure — why the most effective brands are using familiar ingredients more intelligently.
SUPPLIER TRANSPARENCY08
Glycine in Supplements: What Most Suppliers Won't Tell You
Debunking the "4x absorption" myth, decoding batch consistency red flags, and the 5-dimension supplier evaluation checklist that separates qualified vendors from commodity traders.
SUPPLY CHAIN · GEOPOLITICS09
Hormuz Supplement Supply Chain: Our Trend Observations
Geopolitical risk mapping for nutraceutical supply chains — how Strait of Hormuz tensions affect raw material logistics, and what procurement teams should monitor for continuity planning.
Evidence, regulation and sourcing in one briefing room.
This series brings together clinical data, supply-chain architecture and compliance guardrails for B2B ingredient conversations. Each topic should be reviewed against the approved specification, available documentation and destination-market requirements before a commercial decision.
Keep the conversation evidence-led.
Follow the series for new procurement intelligence, or share a sourcing question with the OFAME GROUP team.
For B2B procurement professionals only. Statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Regulatory status current as of June 2026. © 2026 OFAME GROUP. All rights reserved.